Organisation paid for research Program year 2024 Source: CMS Open Payments

Healthlink TMG LLC

Neither a doctor nor a teaching hospital

Research payments

$428,916

269 payments

Through program year 2024, Healthlink TMG LLC is reported as receiving $428,916 in research payments, across 269 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $11,326 5
2023 Research $95,289 14
2022 Research $66,713 82
2021 Research $82,329 110
2020 Research $73,963 40
2019 Research $99,295 18

Breakdown

Who paid Research payments · program years 2019–2024
  1. Esperion Therapeutics, Inc. $190,867 221 payments
  2. Abbott Laboratories $180,191 41 payments
  3. AstraZeneca Pharmaceuticals LP $47,632 4 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $10,226 3 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $190,867 221 payments
  2. Hemodynamic-GUIDEd Management of Heart Failure $42,837 4 payments
  3. A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions. $28,344 7 payments
  4. Hemodynamic-GUIDEd Management of Heart Failure $27,483 8 payments
  5. A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Roxadustat AZD9941 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis $26,316 1 payment
  6. Hemodynamic Guided Monitoring in Heart Failure (HF) Trial $24,114 4 payments
  7. Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes $21,316 3 payments
  8. Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) $19,715 3 payments
  9. His Bundle Pacing Pacemaker Mapping Registry $18,049 4 payments
  10. ABSORB III Randomized Controlled Trial (RCT) (ABSORB-III) $15,800 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record